In view of these encouraging findings showing that selective miRNA antagonism sensitizes GBM tumors to TRAIL administration, more potential miRNAs involved in regulation of TRAIL resistance should be identified in future studies to increase the therapeutic response of TRAIL. This evidence concerns the gene TNFSF10 and glioblastoma.